ImmunityBio, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$502M
↑+31.1% +$119Mvs FY2024
Total Liabilities
$1.00B
↑+15.0% +$130Mvs FY2024
Cash
$88M
↓-38.4% -$55Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $502M | $383M |
| Current Assets | $315M | $185M |
| Cash | $88M | $143M |
| ST Investments | $154M | $6M |
| Receivables | $43M | $2M |
| Inventory | $910K | $8M |
| Other Current | $29M | $24M |
| Non-Current Assets | $187M | $198M |
| PPE | $114M | $137M |
| Goodwill | $910K | $910K |
| Intangibles | $13M | $15M |
| Investments | $0 | $0 |
| Other Non-Current | $59M | $46M |
| Total Liab+Eq | $501M | $382M |
| Current Liab. | $62M | $55M |
| Accounts Payable | $0 | $0 |
| Short-Term Debt | $2M | $1M |
| Deferred Revenue | $0 | $0 |
| Other CL | $60M | $54M |
| Non-Current Liab. | $940M | $816M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $940M | $816M |
| Equity | $-500M | $-489M |
| Retained Earnings | $3.73B | $3.38B |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · IBRX · Comparing FY2025 vs FY2024